PT150 not checked
Pop Test Oncology LLC · Formerly ORG34517
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will ingest PT150 (0, 225, 450 mg) twice daily (e.g., 0800, 2000h) for 5 five days prior to the conduct of the experimental sessions. The sequence of PT150 doses will be quasi-random such that participants will be maintained on the lower dose of PT150 (i.e., 225 mg twice/day) before the higher dose.”In the company’s words, NCT06712602 on ClinicalTrials.gov
- Tested for
- Alcohol Use Disorder
- Main trialPhase 1
- “The goal of this study is to learn if PT150 can reduce the behavioral and physical effects of stress, alcohol, and alcohol use in people with alcohol use disorder.”In the company’s words, NCT06712602 on ClinicalTrials.gov
- Other names
- Formerly ORG34517
Other drugs for Alcohol Use Disorder
- Naltrexone implantShenzhen Sciencare Medical Industries Co., Ltd. · Phase 3
- BrenipatideEli Lilly · Phase 3
- CMND-100Clearmind Medicine Inc. · Phase 1/2
- AFA-281Afasci Inc · Phase 2
- ALN-CIDEBRegeneron · Alnylam · Phase 2
- NTX-2001Newleos Therapeutics, Inc. · Phase 1
Coming up1
- 31 Jul 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 Jul 2028 | PT150 Drug for Use in Alcohol Use Disorder | |
| Phase 1Completed | 27 Oct 2023 | Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026